Title,Authors,Platform,Cited_url,Cited_count,Year
Capecitabine as adjuvant treatment for stage III colon cancer,"C Twelves, A Wong, MP Nowacki, M Abt, H Burris III, A Carrato, J Cassidy, ...","New England Journal of Medicine 352 (26), 2696-2704",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7702472235632109707,1325,2005
Inhibition of cancer cell growth by ruthenium (II) arene complexes,"RE Morris, RE Aird, P del Socorro Murdoch, H Chen, J Cummings, ...","Journal of medicinal chemistry 44 (22), 3616-3621",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14790038684645136620,739,2001
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer,"C Feig, JO Jones, M Kraman, RJB Wells, A Deonarine, DS Chan, ...","Proceedings of the National Academy of Sciences 110 (50), 20212-20217",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4060224797525852193,631,2013
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer,"MA Jacobetz, DS Chan, A Neesse, TE Bapiro, N Cook, KK Frese, C Feig, ...","Gut 62 (1), 112-120",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7284011023258470164,599,2013
 and ,"RE Aird, J Cummings, AA Ritchie, M Muir, RE Morris, H Chen, PJ Sadler, ...","British journal of cancer 86 (10), 1652",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9422878392377083856,579,2002
"Structure− activity relationships for cytotoxic ruthenium (II) arene complexes containing N, N-, N, O-, and O, O-chelating ligands","A Habtemariam, M Melchart, R Fernández, S Parsons, IDH Oswald, ...","Journal of medicinal chemistry 49 (23), 6858-6868",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1482363176784964008,413,2006
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.,"DI Jodrell, MJ Egorin, RM Canetta, P Langenberg, EP Goldbloom, ...","Journal of clinical oncology 10 (4), 520-528",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16068218173175201927,405,1992
"Oral capecitabine as an alternative to iv 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial","W Scheithauer, J McKendrick, S Begbie, M Borner, WI Burns, HA Burris, ...","Annals of Oncology 14 (12), 1735-1743",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2150424708773694386,317,2003
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer,"KK Frese, A Neesse, N Cook, TE Bapiro, MP Lolkema, DI Jodrell, ...","Cancer discovery 2 (3), 260-269",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5154339303607331845,300,2012
Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity,"F Wang, A Habtemariam, EPL van der Geer, R Fernández, M Melchart, ...","Proceedings of the National Academy of Sciences 102 (51), 18269-18274",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13217494381353831376,251,2005
"Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer","LW Seymour, DR Ferry, DJ Kerr, D Rea, M Whitlock, R Poyner, C Boivin, ...","International journal of oncology 34 (6), 1629-1636",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15901907416001053576,248,2009
Tuning the reactivity of osmium (II) and ruthenium (II) arene complexes under physiological conditions,"AFA Peacock, A Habtemariam, R Fernández, V Walland, FPA Fabbiani, ...","Journal of the American Chemical Society 128 (5), 1739-1748",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6243284219049008564,232,2006
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer,"I Chau, AR Norman, D Cunningham, D Tait, PJ Ross, T Iveson, M Hill, ...","Annals of Oncology 16 (4), 549-557",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4160577652183639875,202,2005
"A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer","ER Brown, KA Charles, SA Hoare, RL Rye, DI Jodrell, RE Aird, R Vora, ...","Annals of oncology 19 (7), 1340-1346",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2431848066474154816,162,2008
"Suramin, an active drug for prostate cancer: interim observations in a phase I trial","MA Eisenberger, LM Reyno, DI Jodrell, VJ Sinibaldi, KH Tkaczuk, ...","JNCI: Journal of the National Cancer Institute 85 (8), 611-621",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13388041462681983889,154,1993
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer,"A Neesse, KK Frese, TE Bapiro, T Nakagawa, MD Sternlicht, TW Seeley, ...","Proceedings of the National Academy of Sciences 110 (30), 12325-12330",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3985683434524721928,146,2013
Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme,"K Patel, J Dickson, S Din, K Macleod, D Jodrell, B Ramsahoye","Nucleic acids research 38 (13), 4313-4324",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11205505848611449238,130,2010
Aspirin activates the NF-κB signalling pathway and induces apoptosis in intestinal neoplasia in two              ,"LA Stark, K Reid, OJ Sansom, FV Din, S Guichard, I Mayer, DI Jodrell, ...","Carcinogenesis 28 (5), 968-976",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15140155273265326953,128,2006
"Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma","DI Jodrell, TRJ Evans, W Steward, D Cameron, J Prendiville, C Aschele, ...","European Journal of Cancer 40 (12), 1872-1877",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10264584006245160284,127,2004
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice,"A Neesse, KK Frese, DS Chan, TE Bapiro, WJ Howat, FM Richards, ...","Gut 63 (6), 974-983",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3015991136923327180,120,2014
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.,"GC Wishart, D Bissett, J Paul, D Jodrell, A Harnett, T Habeshaw, DJ Kerr, ...","Journal of clinical oncology 12 (9), 1771-1777",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4427193761229320980,114,1994
"Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes","CA Watts, FM Richards, A Bender, PJ Bond, O Korb, O Kern, M Riddick, ...","Chemistry & biology 20 (11), 1399-1410",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9374758659137855098,107,2013
Combenefit: an interactive platform for the analysis and visualization of drug combinations,"GY Di Veroli, C Fornari, D Wang, S Mollard, JL Bramhall, FM Richards, ...","Bioinformatics 32 (18), 2866-2868",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6172987225459385774,102,2016
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer,"A Saini, AR Norman, D Cunningham, I Chau, M Hill, D Tait, T Hickish, ...","British journal of cancer 88 (12), 1859",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13837762526495155225,102,2003
Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors,"D Hochhauser, T Meyer, VJ Spanswick, J Wu, PH Clingen, P Loadman, ...","Clinical Cancer Research 15 (6), 2140-2147",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6132452778530646671,96,2009
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer,"E Dean, D Jodrell, K Connolly, S Danson, J Jolivet, J Durkin, S Morris, ...","Journal of Clinical Oncology 27 (10), 1660-1666",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9983284854273816962,96,2009
"Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure …","J Cassidy, C Twelves, D Cameron, W Steward, K O'Byrne, D Jodrell, ...","Cancer chemotherapy and pharmacology 44 (6), 453-460",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10573604365352317663,95,1999
Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.,"MA Eisenberger, VJ Sinibaldi, LM Reyno, R Sridhara, DI Jodrell, ...","Journal of clinical oncology 13 (9), 2174-2186",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4927525693969444787,95,1995
Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect,"RL Hayward, JS Macpherson, J Cummings, BP Monia, JF Smyth, ...","Molecular cancer therapeutics 3 (2), 169-178",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1827430567299089549,93,2004
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of …,"M Joerger, ADR Huitema, DJ Richel, C Dittrich, N Pavlidis, E Briasoulis, ...","Clinical Cancer Research 13 (21), 6410-6418",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9074075600750363736,91,2007
ERβ isoform expression in colorectal carcinoma: an ,"NACS Wong, RDG Malcomson, DI Jodrell, NP Groome, DJ Harrison, ...",The Journal of Pathology: A Journal of the Pathological Society of Great …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4017743168387656240,91,2005
Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives,"J Cummings, BT Ethell, L Jardine, G Boyd, JS Macpherson, B Burchell, ...","Cancer research 63 (23), 8443-8450",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2213348237928686206,91,2003
Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD,"BK Ubhi, KK Cheng, J Dong, T Janowitz, D Jodrell, R Tal-Singer, ...","Molecular BioSystems 8 (12), 3125-3133",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9246841066703266657,84,2012
"Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors","J Baselga, A Cervantes, E Martinelli, I Chirivella, K Hoekman, HI Hurwitz, ...","Clinical cancer research 16 (19), 4876-4883",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10076013796120350228,84,2010
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer,"R Camidge, B Reigner, J Cassidy, S Grange, M Abt, E Weidekamm, ...","J Clin Oncol 23 (21), 4719-4725",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16138689534018943945,84,2005
Predictive in vivo animal models and translation to clinical trials,"N Cook, DI Jodrell, DA Tuveson","Drug discovery today 17 (5-6), 253-260",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9367394187624759386,82,2012
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma,"N Cook, KK Frese, TE Bapiro, MA Jacobetz, A Gopinathan, JL Miller, ...","Journal of Experimental Medicine 209 (3), 437-444",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4168602044496691244,81,2012
Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity,"TR Flint, T Janowitz, CM Connell, EW Roberts, AE Denton, AP Coll, ...","Cell metabolism 24 (5), 672-684",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16153106140667881004,78,2016
Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients,"B Reigner, S Clive, J Cassidy, D Jodrell, R Schulz, T Goggin, L Banken, ...","Cancer chemotherapy and pharmacology 43 (4), 309-315",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16338113454560122597,77,1999
"Loss of P53 function activates JAK2–STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient …","SM Wörmann, L Song, J Ai, KN Diakopoulos, MU Kurkowski, K Görgülü, ...","Gastroenterology 151 (1), 180-193. e12",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8239811166238472225,76,2016
"Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium (II …","RL Hayward, QC Schornagel, R Tente, JS Macpherson, RE Aird, ...","Cancer chemotherapy and pharmacology 55 (6), 577-583",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11652442767095490107,72,2005
Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo,"FM Richards, CJ Tape, DI Jodrell, G Murphy","PloS one 7 (7), e40597",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4666311371908694731,71,2012
"Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma","N Wong, L Brett, M Stewart, A Leitch, DB Longley, MG Dunlop, ...","British journal of cancer 85 (12), 1937",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1934945410796410818,71,2001
"The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5, 8-dideazafolic acid (ICI 198583)","AL Jackman, DR Newell, W Gibson, DI Jodrell, GA Taylor, JA Bishop, ...","Biochemical pharmacology 42 (10), 1885-1895",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10157551371849013659,71,1991
Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium (II) based organo-metallic compounds,"SM Guichard, R Else, E Reid, B Zeitlin, R Aird, M Muir, M Dodds, H Fiebig, ...","Biochemical pharmacology 71 (4), 408-415",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14928123060809599151,70,2006
Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins,"J Cummings, N Zelcer, JD Allen, D Yao, G Boyd, M Maliepaard, ...","Biochemical pharmacology 67 (1), 31-39",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1116953009377739952,68,2004
Use of adaptive control with feedback to individualize suramin dosing,"HI Scher, DI Jodrell, JM Iversen, T Curley, W Tong, MJ Egorin, A Forrest","Cancer research 52 (1), 64-70",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8151156664026432728,67,1992
"Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity","RL Hayward, JS Macpherson, J Cummings, BP Monia, JF Smyth, ...","Clinical cancer research 9 (7), 2856-2865",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6712296400280529566,66,2003
An automated fitting procedure and software for dose-response curves with multiphasic features,"GY Di Veroli, C Fornari, I Goldlust, G Mills, SB Koh, JL Bramhall, ...","Scientific reports 5, 14701",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13363724148788589843,65,2015
"Structure− Activity Relationships of Monomeric C2-Aryl Pyrrolo [2, 1-c][1, 4] benzodiazepine (PBD) Antitumor Agents","D Antonow, M Kaliszczak, GD Kang, M Coffils, AC Tiberghien, N Cooper, ...","Journal of medicinal chemistry 53 (7), 2927-2941",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18169851382172714038,64,2010
Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies,"SM Guichard, I Mayer, DI Jodrell","Journal of chromatography B 826 (1-2), 232-237",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12205162580349274034,64,2005
The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines,"JM Sewell, I Mayer, SP Langdon, JF Smyth, DI Jodrell, SM Guichard","European Journal of Cancer 41 (11), 1637-1644",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3789145901030653603,63,2005
Developing and piloting a nurse-led model of follow-up in the multidisciplinary management of colorectal cancer,"G Knowles, L Sherwood, MG Dunlop, G Dean, D Jodrell, C McLean, ...","European Journal of Oncology Nursing 11 (3), 212-223",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6291654816410122316,61,2007
Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics,"DR Newell, SS Burtles, BW Fox, DI Jodrell, TA Connors","British journal of cancer 81 (5), 760",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8094813958002128109,61,1999
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation,"J Cummings, G Boyd, BT Ethell, JS Macpherson, B Burchell, JF Smyth, ...","Biochemical pharmacology 63 (4), 607-613",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12556183017915575809,59,2002
Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.,"DI Jodrell, LM Reyno, R Sridhara, MA Eisenberger, KH Tkaczuk, ...","Journal of clinical oncology 12 (1), 166-175",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8375701882300900397,59,1994
"A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma","SM Rudman, MB Jameson, MJ McKeage, P Savage, DI Jodrell, M Harries, ...","Clinical Cancer Research 17 (7), 1998-2005",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15218681715836280119,58,2011
Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor direct evidence for biased agonism,"AC MacKinnon, C Waters, D Jodrell, C Haslett, T Sethi","Journal of Biological Chemistry 276 (30), 28083-28091",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16472320392156609829,58,2001
Cyclin D1 overexpression in colorectal carcinoma ,"N Wong, RG Morris, A McCondochie, S Bader, DI Jodrell, DJ Harrison","The Journal of pathology 197 (1), 128-135",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16398027146545086721,57,2002
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer,"E Hessmann, MS Patzak, L Klein, N Chen, V Kari, I Ramu, TE Bapiro, ...","Gut 67 (3), 497-507",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5060538221402879094,55,2018
"Phase I study of AZD0530, an oral potent inhibitor of Src kinase: first demonstration of inhibition of Src activity in human cancers","J Tabernero, A Cervantes, K Hoekman, HI Hurwitz, DI Jodrell, P Hamberg, ...","Journal of Clinical Oncology 25 (18_suppl), 3520-3520",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6806816092105384669,55,2007
γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000),"J Wu, PH Clingen, VJ Spanswick, M Mellinas-Gomez, T Meyer, I Puzanov, ...","Clinical Cancer Research 19 (3), 721-730",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7821429095191027774,53,2013
Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136,"SM Guichard, JS Macpherson, DE Thurston, DI Jodrell","European Journal of Cancer 41 (12), 1811-1818",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13663418619657337622,51,2005
Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials,"RJ Brais, SE Davies, M O’Donovan, BW Simpson, N Cook, WC Darbonne, ...","Pancreatology 12 (1), 8-15",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7028729879292583394,50,2012
GEMMs as preclinical models for testing pancreatic cancer therapies,"A Gopinathan, JP Morton, DI Jodrell, OJ Sansom","Disease models & mechanisms 8 (10), 1185-1200",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=615073086725682912,49,2015
Adaptive designs for dual-agent phase I dose-escalation studies,"JA Harrington, GM Wheeler, MJ Sweeting, AP Mander, DI Jodrell","Nature Reviews Clinical Oncology 10 (5), 277",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12420821525978890339,49,2013
Population pharmacokinetics of gentamicin in patients with cancer,"MC Rosario, AH Thomson, DI Jodrell, CA Sharp, HL Elliott","British journal of clinical pharmacology 46 (3), 229",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8743140112216884734,48,1998
mTORC2 signaling drives the development and progression of pancreatic cancer,"DR Driscoll, SA Karim, M Sano, DM Gay, W Jacob, J Yu, Y Mizukami, ...","Cancer research 76 (23), 6911-6923",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16710074699501209983,47,2016
"Vegfa signals through ERK to promote angiogenesis, but not artery differentiation","M Shin, TJ Beane, A Quillien, I Male, LJ Zhu, ND Lawson","Development 143 (20), 3796-3805","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2992222224658083487,7275305052013019958,5414797748764207755",46,2016
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.,"LM Reyno, MJ Egorin, RM Canetta, DI Jodrell, KD Swenerton, JL Pater, ...","Journal of clinical oncology 11 (6), 1156-1164",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3553176534515222653,46,1993
CHK1 inhibition synergizes with gemcitabine initially by destabilizing the DNA replication apparatus,"SB Koh, A Courtin, RJ Boyce, RG Boyle, FM Richards, DI Jodrell","Cancer research 75 (17), 3583-3595",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17436180792737140485,45,2015
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.,"K Kobayashi, DI Jodrell, MJ Ratain","Cancer surveys 17, 51-78",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=267848686018963857,43,1993
"A novel method for quantification of gemcitabine and its metabolites 2′, 2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19 …","TE Bapiro, FM Richards, MA Goldgraben, KP Olive, B Madhu, KK Frese, ...","Cancer chemotherapy and pharmacology 68 (5), 1243-1253",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4253102731021627071,42,2011
The pharmacokinetics of the quinazoline antifolate ICID 1694 in mice and rats,"DI Jodrell, DR Newell, W Gibson, LR Hughes, AH Calvert","Cancer chemotherapy and pharmacology 28 (5), 331-338",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17772814489968524669,42,1991
Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling,"S Arnould, VJ Spanswick, JS Macpherson, JA Hartley, DE Thurston, ...","Molecular cancer therapeutics 5 (6), 1602-1609",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15716088133676976605,41,2006
"Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro","K Connolly, R Mitter, M Muir, D Jodrell, S Guichard","Cancer chemotherapy and pharmacology 64 (2), 307-316",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13471766255327606821,40,2009
The renal effects of N,"DI Jodrell, DR Newell, SE Morgan, S Clinton, JPM Bensted, LR Hughes, ...","British journal of cancer 64 (5), 833",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=947042132386265642,40,1991
 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136,"RE Aird, M Thomson, JS Macpherson, DE Thurston, DI Jodrell, ...","The pharmacogenomics journal 8 (4), 289",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10692148135568093396,39,2008
Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer,"KC Connolly, H Gabra, CJ Millwater, KJ Taylor, GJ Rabiasz, JEV Watson, ...","Cancer research 59 (12), 2806-2809",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3338084484607366747,38,1999
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients,"M Joerger, ADR Huitema, DJ Richel, C Dittrich, N Pavlidis, E Briasoulis, ...","Clinical pharmacokinetics 46 (12), 1051-1068",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9431689942235593080,37,2007
5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer,"DI Jodrell, M Stewart, R Aird, G Knowles, A Bowman, L Wall, J Cummings, ...","British journal of cancer 84 (5), 600",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7985060719754400136,37,2001
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted …,"I Chau, AR Norman, D Cunningham, T Iveson, M Hill, T Hickish, F Lofts, ...","European Journal of Cancer 41 (11), 1551-1559",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3157531661441230252,36,2005
"A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly","LK Dawson, DI Jodrell, A Bowman, R Rye, B Byrne, A Bernareggi, ...","European Journal of Cancer 36 (18), 2353-2359",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3557169504294854423,36,2000
The perceived information needs of patients receiving adjuvant chemotherapy for surgically resected colorectal cancer,"G Knowles, A Tierney, D Jodrell, A Cull","European Journal of Oncology Nursing 3 (4), 208-220",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9050562741731007949,36,1999
Whole-genome sequencing coupled to imputation discovers genetic signals for anthropometric traits,"I Tachmazidou, D Süveges, JL Min, GRS Ritchie, J Steinberg, K Walter, ...","The American Journal of Human Genetics 100 (6), 865-884","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11497197761131768047,14092388418632830455",35,2017
High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and …,"G Boyd, JF Smyth, DI Jodrell, J Cummings","Analytical biochemistry 297 (1), 15-24",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8920134773248072419,34,2001
Modeling toxicity and response in carboplatin-based combination chemotherapy.,"MJ Egorin, LM Reyno, RM Canetta, DI Jodrell, KD Swenerton, JL Pater, ...","Seminars in oncology 21 (5 Suppl 12), 7-19",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=578755363356036106,34,1994
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer,"DI Jodrell, IE Smith, JL Mansi, MC Pearson, G Walsh, S Ashley, ...","British journal of cancer 63 (5), 794",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13399614281641099896,34,1991
"ICI D1694, an inhibitor of thymidylate synthase for clinical study","AL Jackman, DI Jodrell, W Gibson, TC Stephens","Purine and Pyrimidine Metabolism in Man VII, 19-23",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13132183631694565516,33,1991
Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate,"DI Jodrell, TJ Iveson, IE Smith","The Lancet 329 (8533), 622",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14063274019110975815,32,1987
Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors,"MA Izquierdo, A Bowman, M García, D Jodrell, M Martinez, B Pardo, ...","Clinical Cancer Research 14 (10), 3105-3112",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17899447555485877975,31,2008
Expression of V,"AC MacKinnon, U Tufail-Hanif, CD Lucas, D Jodrell, C Haslett, T Sethi","British journal of cancer 92 (3), 522",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14881577758984346995,29,2005
Anti-cancer compounds,"GMF Bisset, AL Jackman, DI Jodrell","US Patent 5,444,061",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1795888370103069079,29,1995
"Impact on the cell cycle and involvement of ATM, ATR, chk1 and chk2 kinases in the cytotoxicity of SJG-136, a new pyrrolobenzodiazepine dimer","S Arnould, JS Macpherson, DE Thurston, DI Jodrell, SM Guichard","Cancer Research 64 (7 Supplement), 1298-1298",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1127612345379342006,27,2004
CSF1R,"JB Candido, JP Morton, P Bailey, AD Campbell, SA Karim, T Jamieson, ...","Cell reports 23 (5), 1448-1460",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16857548630138625747,26,2018
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer,"A Courtin, FM Richards, TE Bapiro, JL Bramhall, A Neesse, N Cook, ...","PloS one 8 (6), e67330",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18291367463346125934,26,2013
"Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells","Y Lin, FM Richards, BF Krippendorff, JL Bramhall, JA Harrington, ...","British journal of cancer 107 (10), 1692",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2236685049609338469,26,2012
"Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies","K Patel, SM Guichard, DI Jodrell","Journal of Chromatography B 863 (1), 19-25",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11251153803436613559,24,2008
"A phase I study of the trinuclear platinum compound, BBRá3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer","C Gourley, J Cassidy, C Edwards, L Samuel, D Bisset, G Camboni, ...","Cancer chemotherapy and pharmacology 53 (2), 95-101",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13436126573730502168,24,2004
Carboplatin in the treatment of metastatic carcinoid tumours and paraganglioma: a phase II study,"DI Jodrell, IE Smith","Cancer chemotherapy and pharmacology 26 (1), 62-64",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13662180673288889429,24,1990
Antimicrobial practice: development of guidelines for gentamicin dosing,"AH Thomson, N Duncan, B Silverstein, S Alcock, D Jodrell","Journal of Antimicrobial Chemotherapy 38 (5), 885-893",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1998626304233396292,23,1996
A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941,"DI Jodrell, LS Murray, J Hawtof, MA Graham, MJ Egorin","Cancer chemotherapy and pharmacology 37 (4), 356-362",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15966031947955087027,23,1996
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma,"N Cook, B Basu, DM Smith, A Gopinathan, J Evans, WP Steward, ...","British journal of cancer 118 (6), 793","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7072949475084754189,4398085640779558863",22,2018
New model for estimating glomerular filtration rate in patients with cancer,"T Janowitz, EH Williams, A Marshall, N Ainsworth, PB Thomas, ...","Journal of Clinical Oncology 35 (24), 2798",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10529466466356007531,22,2017
Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin,"IR Whittle, G Malcolm, DI Jodrell, M Reid","British journal of neurosurgery 13 (2), 132-137",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12475540979294412306,22,1999
"Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity","SM Guichard, JS Macpherson, I Mayer, E Reid, M Muir, M Dodds, ...","European Journal of Cancer 44 (2), 310-317",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12641243623607577824,21,2008
Prognosis without treatment as a modifier in health economic assessments,"R Camidge, A Walker, JJ Oliver, F Nussey, S Maxwell, D Jodrell, DJ Webb","Bmj 330 (7504), 1382-1384",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9912909648508914788,21,2005
"Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist","S Clive, DJ Webb, A MacLellan, A Young, B Byrne, L Robson, JF Smyth, ...","Clinical cancer research 7 (10), 3071-3078",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15766819446085868023,21,2001
Gastrin‐releasing peptide is a potent vasodilator in humans,"S Clive, D Jodrell, D Webb","Clinical Pharmacology & Therapeutics 69 (4), 252-259",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4669550290052165386,21,2001
A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours,"L Wall, DC Talbot, P Bradbury, DI Jodrell","British journal of cancer 90 (4), 800",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13089772809825699214,20,2004
Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg,"CM Waters, AC MacKinnon, J Cummings, U Tufail-Hanif, D Jodrell, ...","British journal of cancer 88 (11), 1808",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16421024663447614762,18,2003
Targeting carcinoembryonic antigen with DNA vaccination: on-target adverse events link with immunologic and clinical outcomes,"KJ McCann, A Mander, A Cazaly, L Chudley, J Stasakova, ...","Clinical Cancer Research 22 (19), 4827-4836",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9313761136029459263,17,2016
Factors influencing the cellular accumulation of SN-38 and camptothecin,"J Cummings, G Boyd, JS Macpherson, H Wolf, G Smith, JF Smyth, ...","Cancer chemotherapy and pharmacology 49 (3), 194-200",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17894812351874559162,17,2002
Understanding the complexity of porous graphitic carbon (PGC) chromatography: modulation of mobile-stationary phase interactions overcomes loss of retention and reduces variability,"TE Bapiro, FM Richards, DI Jodrell","Analytical chemistry 88 (12), 6190-6194",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16067730679154462907,16,2016
Formula-based dosing for carboplatin,DI Jodrell,"European Journal of Cancer 35 (9), 1299-1301",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14751609018960084435,15,1999
A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™(nolatrexed dihydrochloride) given by 10-day oral administration,"DI Jodrell, A Bowman, R Rye, B Byrne, A Boddy, I Rafi, GA Taylor, ...","British journal of cancer 79 (5), 915",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15312956048055497845,15,1999
A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK‐0752 in pancreatic cancer,"J Whitehead, H Thygesen, T Jaki, S Davies, S Halford, H Turner, N Cook, ...","Statistics in medicine 31 (18), 1931-1943",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2395057900048899152,14,2012
Utility of individualized carboplatin dosing alone and in combination regimens.,"MJ Egorin, DI Jodrell","Seminars in oncology 19 (1 Suppl 2), 132-138",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=500267671454568471,14,1992
Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer,"RE Morris, PJ Sadler, H Chen, D Jodrell","US Patent 6,750,251","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13191241782855008830,16636061328955710946",13,2004
The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction,"LS Murray, DI Jodrell, JG Morrison, A Cook, DJ Kerr, B Whiting, SB Kaye, ...","Clinical Oncology 10 (1), 35-38",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5637055610995916872,13,1998
"The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice","DI Jodrell, W Gibson, GMF Bisset, FT Boyle, IR Judson, AL Jackman","Biochemical pharmacology 46 (12), 2229-2234",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4171830326883797433,13,1993
Pharmacokinetics and early clinical studies of selected new drugs.,"SB Kaye, P Workman, MA Graham, J Cassidy, D Jodrell","Cancer surveys 17, 371-396",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14198245830853494617,13,1993
Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer,"DC Smith, DI Jodrell, MJ Egorin, RM Ambinder, EG Zuhowski, W Kreis, ...","Cancer chemotherapy and pharmacology 31 (5), 363-368",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16753121334343820567,12,1993
Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models ,"TE Bapiro, KK Frese, A Courtin, JL Bramhall, B Madhu, N Cook, A Neesse, ...","British journal of cancer 111 (2), 318",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6894820734449805184,11,2014
Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters,"M Kaliszczak, D Antonow, KI Patel, P Howard, DI Jodrell, DE Thurston, ...","The AAPS journal 12 (4), 617-627",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6806526159312553153,11,2010
The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes,"DR Camidge, JJ Oliver, C Skinner, B Attwood, F Nussey, D Jodrell, ...","British journal of clinical pharmacology 65 (2), 224-229",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12318588372095019890,11,2008
"Dose-limiting neurotoxicity in a Phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic α-picoline derivative, administered intravenously","DI Jodrell, A Bowman, M Stewart, N Dunlop, R French, A MacLellan, ...","British journal of cancer 77 (5), 808",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7216970055248652000,11,1998
"Pharmacokinetic studies with the antifolate C 2-desamino-C 2-methyl-N 10-propargyl-2'-trifluoromethyl-5, 8-dideazafolic acid (CB3988) in mice and rats using in vivo 19 F-NMR …","DR Newell, RJ Maxwell, GMF Bisset, DI Jodrell, JR Griffiths","British journal of cancer 62 (5), 766",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10037564984950492958,11,1990
The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression,"Y Wallez, CR Dunlop, TI Johnson, SB Koh, C Fornari, JWT Yates, ...","Molecular cancer therapeutics 17 (8), 1670-1682",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8411172387635316218,10,2018
Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes,"CM Connell, S Raby, I Beh, TR Flint, EH Williams, DT Fearon, DI Jodrell, ...","Annals of Oncology 28 (7), 1678-1679",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16703259059197795698,10,2017
A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level,"SB Koh, P Mascalchi, E Rodriguez, Y Lin, DI Jodrell, FM Richards, ...","J Cell Sci 130 (2), 512-520",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=254508046956447808,10,2017
Retroperitoneal surgery: its wider role in the management of malignant teratoma,"GW Hollins, S Thomas, DJ Lanigan, N Dahar, D Jodrell, SB Kaye, D Kirk","British journal of urology 77 (4), 571-576",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8378859320704246491,10,1996
Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support,"D Bissett, D Jodrell, AN Harnett, T Habeshaw, SB Kaye, D Evans, ...","British journal of cancer 71 (6), 1279",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8695128913349572905,10,1995
The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.,"DI Jodrell, AT Irvine, VR McCready, E Woodcraft, IE Smith","British journal of cancer 58 (5), 663",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1948073080422062289,10,1988
Mechanistic distinctions between CHK1 and WEE1 inhibition guide the scheduling of triple therapy with gemcitabine,"SB Koh, Y Wallez, CR Dunlop, SB de Quirós Fernández, TE Bapiro, ...","Cancer research 78 (11), 3054-3066",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=960234659727856227,9,2018
How many cisplatin administration protocols does your department use?,"AP Greystoke, DI Jodrell, M Cheung, I Rivans, MJ Mackean","European journal of cancer care 19 (1), 80-90",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6681143473022092224,9,2010
A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors,"M Ranson, C Dive, T Ward, J Cummings, K Connolly, S Evans, L Robson, ...","Journal of Clinical Oncology 24 (18_suppl), 3059-3059",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1336633920155110484,9,2006
Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer,"RE Morris, PJ Sadler, H Chen, D Jodrell","US Patent 6,979,681",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13159683208737435203,9,2005
A phase I trial of AEG35156 (XIAP antisense) administered as a 7-day continuous intravenous infusion in patients with advanced tumors,"M Ranson, C Dive, TH Ward, J Cummings, K Connolly, S Evans, ...","Clin Cancer Res 11 (24  Part 2), 8965s-9216s",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14594278810309013362,9,2005
Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes,"JS Macpherson, DI Jodrell, SM Guichard","Analytical biochemistry 350 (1), 71-80",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9601078769850250197,8,2006
Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model,"SM Guichard, ML Hua, P Kang, JS Macpherson, DI Jodrell","Cancer chemotherapy and pharmacology 60 (5), 651-660",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17351489954553569881,7,2007
Ruthenium (II) compounds for use in the therapy of cancer,"RE Morris, PJ Sadler, D Jodrell, H Chen","US Patent 6,936,634","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2134859093839943710,8033005070035468419",7,2005
"Phase I (PI) trials with aplidine (APL), a new marine derived anticancer compound","E Raymond, L Paz-Ares, M Izquierdo, K Belanger, J Maroun, A Bowman, ...","European Journal of Cancer 37, S32",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12289278130888325692,7,2001
"Development of a gradient elution high-performance liquid chromatography assay with ultraviolet detection for the determination in plasma of the anticancer peptide [Arg6, D …","J Cummings, AJ MacLellan, M Mark, DI Jodrell",Journal of Chromatography B: Biomedical Sciences and Applications 732 (2 …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11177982026085727261,7,1999
"Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.","S Deva, RD Baird, N Cresti, J Garcia-Corbacho, L Hogarth, EP Frenkel, ...","Journal of Clinical Oncology 33 (15_suppl), 2511-2511",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=882112946672665259,6,2015
The EGFR demonstrates linear signal transmission,"DA Oyarzún, JL Bramhall, F López-Caamal, FM Richards, DI Jodrell, ...","Integrative Biology 6 (8), 736-742",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15176493029213559685,6,2014
Phase 1 Study Of A Sequence Selective Minor Groove DNA Binding Agent (SJG-136) with Pharmacokinetic and Pharmacodynamic Measurements in Patients with Advanced Solid Tumours.,"D Hochhauser, T Meyer, VJ Spanswick, J Wu, PH Clingen, PM Loadman, ...",,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1984095285047114368,6,2009
"AEG35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolated from pre-clinical models and from patients","E Lacasse, S Morris, T Ward, J Cumings, L Robson, K Di Tullio, D Méthot, ...","Cancer Research 66 (8 Supplement), 1142-1142",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1933619839780762378,6,2006
A randomised comparison between six months of bolus fluorouracil (5-FU)/leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in …,"N Starling, I Chau, AR Norman, D Tait, T Iveson, M Hill, T Hickish, F Lofts, ...","Journal of Clinical Oncology 22 (14_suppl), 3523-3523","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16466158094455499995,14819988202867549967",6,2004
"RM175, a novel ruthenium (Ru-11) organo-metallic complex: Patterns of resistance in vitro and in vivo","RE Aird, J Cummings, R Morris, AA Ritchie, PJ Sadler, DI Jodrell","BRITISH JOURNAL OF CANCER 85, 101-101",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15308421793601880995,6,2001
Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?,"DI Jodrell, LS Murray, NS Reed, PA Canney, SB Kaye, J Cassidy","British journal of cancer 70 (4), 749",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4444522718554466911,6,1994
"Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses","S Spencer, SK Bal, W Egner, HL Allen, SI Raza, CA Ma, M Gürel, Y Zhang, ...","Journal of Experimental Medicine, jem. 20190344",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5129385243904175907,5,2019
Ruthenium anticancer complexes,"P Sadler, R Lainez, A Habtemariam, M Melchart, D Jodrell","US Patent App. 10/520,239",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6687954915197388424,5,2006
Kahalalide F appears to promote necrotic cell death in hepatoma cell lines,"JM Sewell, SP Langdon, JF Smyth, DI Jodrell, S Guichard","Cancer Research 64 (7 Supplement), 347-348",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4718326792113058546,5,2004
Glucuronidation as a de novo mechanism of drug resistance in colon cancer cells.,"J Cummings, G Boyd, BT Ethell, JS Macpherson, B Burchell, JF Smyth, ...","CLINICAL CANCER RESEARCH 6, 4505S-4505S",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15074164113059730874,5,2000
A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma,"MJ Mackean, D Kerr, M Lesko, A Svedberg, F Hansson, D Jodrell, ...","British journal of cancer 78 (12), 1620",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10371576824579424281,5,1998
Effects of nitric oxide manipulation on the disposition of platinum in an experimental glioma model,"GP Malcolm, DI Jodrell, A MacLellan, GR Swaroop, PAT Kelly, IR Whittle","Neuroreport 9 (2), 181-185",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8464241467936545749,5,1998
"Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours","J Spicer, R Baird, A Suder, N Cresti, JG Corbacho, L Hogarth, E Frenkel, ...","European Journal of Cancer 51 (2), 137-145",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5023075827007772769,4,2015
Oxidative stress,LL Ji,"Encyclopedia of Exercise Medicine in Health and Disease, 679-681",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13551349741769303845,4,2012
"A phase I study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma (MM) or renal cell carcinoma (RCC)","JF Spicer, MB Jameson, P Savage, D Jodrell, SM Rudman, F Erlandsson, ...","Journal of Clinical Oncology 27 (15S), 3024-3024",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4675830288013372375,4,2009
"Absorption, metabolism, and excretion of ","MM Woo, L Rodriguez, H Gu, K Crenshaw-Williams, F Rocha, ...","Journal of Clinical Oncology 25 (18_suppl), 2564-2564",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=358020418424061920,4,2007
Epirubicin chemotherapy and advanced breast cancer after adjuvant CMF chemotherapy,"D Bissett, J Paul, G Wishart, D Jodrell, MA Machan, A Harnett, P Canney, ...","Clinical Oncology 7 (1), 12-15",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14630776073240256690,4,1995
γ-Linked Dipeptide Analogues of 2-Desamino-2-Methyl-N,"AL Jackman, GMF Bisset, DI Jodrell, W Gibson, R Kimbell, V Bavetsias, ...","Chemistry and Biology of Pteridines and Folates, 579-584",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8687631305172845452,4,1993
Understanding hematological toxicities using mathematical modeling,"C Fornari, LO O'Connor, JWT Yates, SYA Cheung, DI Jodrell, JT Mettetal, ...","Clinical Pharmacology & Therapeutics 104 (4), 644-654",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5736525459088688177,3,2018
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic …,"P Corrie, W Qian, B Basu, JW Valle, S Falk, C Iwuji, HS Wasan, ...","Journal of Clinical Oncology 35 (15_suppl), 4100-4100",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4283603152795352430,3,2017
Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy,"RC Jackson, GY Di Veroli, SB Koh, I Goldlust, FM Richards, DI Jodrell","PLoS computational biology 13 (5), e1005529",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13404414637144106533,3,2017
The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data,"AB Gill, G Anandappa, AJ Patterson, AN Priest, MJ Graves, T Janowitz, ...","Magnetic resonance imaging 33 (2), 246-251",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17739631308397698488,3,2015
Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer,"R Morris, P Sadler, H Chen, D Jodrell","US Patent App. 11/165,372",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13632740268505988787,3,2005
"Efficacy, safety, and cost of new anticancer drugs: Pessimistic conclusion was not justified","H Calvert, DI Jodrell, J Cassidy, AL Harris","BMJ: British Medical Journal 325 (7375), 1302",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17544201668518186931,3,2002
"Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation","MJ Mackean, J Cassidy, DI Jodrell, J Paul, NS Reed, PA Canney, H Yosef, ...","British journal of cancer 77 (9), 1480",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11427531239986256177,3,1998
"Suramin, an active drug for prostate cancer: interim observations in a phase I trial","MA Eisenberger, LM Reyno, DI Jodrell","JNCI: Journal of the National Cancer Institute 86 (8), 639-640",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2261221430464264351,3,1994
A phase I–II study of N-(phosphonacetyl)-l-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer,"DI Jodrell, W Oster, DJ Kerr, PA Canney, H Yosef, WP Steward, SB Kaye, ...","European Journal of Cancer 30 (7), 950-954",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3174077265242400607,3,1994
"INVITRO AND INVIVO STUDIES WITH 2-DESAMINO-2-CH3-N-10-PROPARGYL-5, 8-DIDEAZAFOLATE (ICI-198583), AN INHIBITOR OF THYMIDYLATE SYNTHASE","A JACKMAN, D NEWELL, D JODRELL, G TAYLOR, J BISHOP, ...",CHEMISTRY AND BIOLOGY OF PTERIDINES 1989-PTERIDINES AND FOLIC ACID …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2479309561561460166,3,1990
"Myelosuppression after methotrexate, mitoxantrone, and mitomycin C","DI Jodrell, TJ Iveson, IE Smith","The Lancet 329 (8543), 1211",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7193073267129476809,3,1987
Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites,"MS Patzak, V Kari, S Patil, FH Hamdan, RG Goetze, M Brunner, ...","EBioMedicine 40, 394-405",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6059015828799091008,2,2019
Cambridge Brain Mets Trial 1 (CamBMT1): A proof of principle study of afatinib penetration into cerebral metastases (mets) for patients (pts) undergoing neurosurgical resection …,"RD Baird, J Garcia-Corbacho, C Linossi, SS Kumar, D Smith, M Williams, ...","Journal of Clinical Oncology 35 (15_suppl), 2008-2008",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16385683053379701995,2,2017
STAR_PAC: A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab¬ Paclitaxel for pancreatic cancer,"H Kocher, DJ Propper, S Alabaf, K Mousa, B North, V Papoutsaki, ...","Pancreatology 3 (16), S4-S5",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17410614825113933080,2,2016
Progress in pancreatic cancer: moving beyond gemcitabine?,"B Basu, D Jodrell","Expert review of anticancer therapy 12 (8), 997-1000",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6945385273350579872,2,2012
"A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.","RD Baird, S Papa, N Cresti, H Hatcher, L Hogarth, M Jamal-Hanjani, ...","Journal of Clinical Oncology 30 (15_suppl), 3100-3100",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13543546290950595113,2,2012
Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC‐PAMM‐NDDG,"M Joerger, ADR Huitema, DJ Richel, C Dittrich, N Pavlidis, E Briasoulis, ...","British journal of clinical pharmacology 63 (4), 505-505",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14495062586248686260,2,2007
Aspirin activates the NF-kB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer,"LA StarkÃ, K Reid, OJ Sansom, FV Din, S Guichard, I Mayer, DI Jodrell, ...","Carcinogenesis 28 (5), 968-976",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=150742750281120472,2,2007
Determination of the glucuronide metabolites of the topoisomerase I inhibitors 7-ethyl 10-hydroxycamptothecin (SN-38) and NU/ICRF 505 by high-performance liquid chromatography,"J Cummings, BT Ethell, G Boyd, B Burchell, JF Smyth, DI Jodrell","Chromatographia 55 (1), S157-S163",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11284382186206423402,2,2002
Novel ruthenium (Ru-II) organo-metallic complexes: In vitro cytotoxicity in wild type and drug resistant A2780 human ovarian cancer cell lines.,"J Cummings, RE Aird, R Morris, H Chen, PD Murdoch, PJ Sadler, ...","CLINICAL CANCER RESEARCH 6, 4494S-4494S",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9648558386834267323,2,2000
Recent developments in adjuvant chemotherapy for colorectal cancer,"GH KNOWLES, DI JODRELL","European journal of cancer care 6 (1), 18-22",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8081008161618955079,2,1997
The relevance of the investigation of clinical pharmacokinetics and pharmacodynamics in medical oncology,"DI Jodrell, MJ Egorin","EXCERPTA MEDICA INTERNATIONAL CONGRESS SERIES 1022 (1), 227-227",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6456163716217673227,2,1993
"A PHASE-II EVALUATION OF TRIMELAMOL (N2, N4, N6-TRIHYDROXYMETHYL-N2, N4, N6-TRIMETHYLMELAMINE) IN STAGE-III-IV OVARIAN-CANCER","IR Judson, ME Gore, LA Gumbrell, K Balmanno, DI Jodrell, TJ Perren, ...","BRIT J CANCER 58 (2), 273-273",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1120028903761279784,2,1988
Identification of resistance pathways specific to malignancy using organoid models of pancreatic cancer,"M Ponz-Sarvise, V Corbo, H Tiriac, DD Engle, KK Frese, TE Oni, ...","Clinical Cancer Research 25 (22), 6742-6755",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17853894372763373191,1,2019
Quantifying drug‐induced bone marrow toxicity using a novel haematopoiesis systems pharmacology model,"C Fornari, LO O'Connor, C Pin, A Smith, JWT Yates, SYA Cheung, ...",CPT: pharmacometrics & systems pharmacology,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5496251116901895691,1,2019
Abstract B54: Genetically engineered mouse-derived allografts (GEDAs): an immunocompetent mouse model of PDAC for the evaluation of novel therapeutic strategies,"S Mollard, KK Frese, A Gopinathan, FM Richards, DI Jodrell","Cancer Research 76 (24 Supplement), B54-B54",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13768224235747398259,1,2016
Gemcitabine uptake and metabolism of cancer associated fibroblasts in murine pancreatic cancer,"M Patzak, E Hessmann, T Bapiro, K Frese, D Jodrell, V Ellenrieder, ...","Zeitschrift für Gastroenterologie 54 (08), KV466",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4549665107660413478,1,2016
747TiPSCHEDULING NAB-PACLITAXEL WITH GEMCITABINE (SIEGE): RANDOMISED PHASE II TRIAL TO INVESTIGATE TWO DIFFERENT SCHEDULES OF NAB-PACLITAXEL (ABX) COMBINED WITH GEMCITABINE …,"P Corrie, W Qian, DI Jodrell, S Lao-Sirieix, P Whittaker, A Gopinathan, ...",Annals of oncology: official journal of the European Society for Medical …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9431101615767690603,1,2014
"Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated …","RD Baird, N Cresti, E Beddowes, M Saggese, M Flynn, JG Corbacho, ...","Cancer Research 73 (24 Supplement), P4-12-24-P4-12-24",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3891846347916206704,1,2013
Phase I study of the DNA minor groove binding pyrrolobenzodiazepine dimer (SJG 136) administered every 21 days in patients with advanced solid tumours,"D Hochhauser, T Meyer, P Loadman, VJ Spanswick, M Cobb, RH Begent, ...","Journal of Clinical Oncology 26 (15_suppl), 2566-2566",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1316063442276689453,1,2008
"Pyrrolo [2, 1-c][1, 4] benzodiazepine (PBD) analogues show differential substrate specificity to ABC transporters","M Kaliszczak, D Antonow, K Patel, D Jodrell, P Howard, D Thurston, ...","Cancer Research 68 (9 Supplement), 3226-3226",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17427192621393545624,1,2008
"Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours.","M Ranson, E Dean, T Ward, J Cummings, L Robson, J Durkin, J Jolivet, ...","Molecular Cancer Therapeutics 6 (11 Supplement), C163-C163",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1026401213852120878,1,2007
BBR2778 a new anthracenedione analogue with no preclinical cardiac toxicity: Results from 3 phases I studies.,"S Faivre, P Borchmann, D Jodrell, G Camboni, A Bernareggi, E Raymond, ...","CLINICAL CANCER RESEARCH 5, 3795S-3795S",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17893565779453065555,1,1999
Influence of the Antacid Maalox ((R)) on the pharmacokinetics (PK) of Xeloda (TM) in cancer patients,"S Clive, J Cassidy, D Jodrell, B Roos, T Goggin, B Reigner","Annals of Oncology 9, 131-131",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11163677948535918154,1,1998
"The population pharmacokinetics of CI941, a novel anthrapyrazole anticancer agent","D Jodrell, A Forrest, J Hawtof, M GRAHAM, AH CALVERT, M EGORIN","CLIN PHARMACOL THER 49 (2), 195-195",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11431939534010297101,1,1991
"The pharmacology and toxicology of novel thymidylate synthase inhibitors, potential new anticancer agents.",DI Jodrell,University of Southampton,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10788395244144365569,1,1990
A Highly Porous Metal-Organic Framework System to Deliver Payloads for Gene Knockdown,"MH Teplensky, M Fantham, C Poudel, C Hockings, M Lu, A Guna, ...","Chem 5 (11), 2926-2941",,0,2019
Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors,"MJ Sale, E Minihane, NR Monks, R Gilley, FM Richards, KP Schifferli, ...","Nature communications 10 (1), 1-19",,0,2019
SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer,"I Ramu, SM Buchholz, MS Patzak, RG Goetze, SK Singh, FM Richards, ...","EBioMedicine 48, 161-168",,0,2019
Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate,"EH Williams, CM Connell, JMJ Weaver, I Beh, H Potts, CT Whitley, N Bird, ...","JNCI cancer spectrum 3 (4), pkz068",,0,2019
The role of ATM and DNA-PK in responding to AZD6738-induced damage in pancreatic ductal adenocarcinoma cells,"CR Dunlop, Y Wallez, SB de Quirós Fernández, SA Karim, A Lau, ...","Cancer Research 79 (13 Supplement), 271-271",,0,2019
"Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses","J Thaventhiran, S Spencer, S Kostel Bal, W Egner, H Lango Allen, ...",Rockefeller University Press,,0,2019
Mechanisms of vascular endothelial growth factor inhibition induced hypertension,"K Maki-Petaja, A McGeoch, L Yang, A Hubsch, C McEniery, F Mir, ...",,,0,2018
Antitumor effect of an oligosaccharide API in a genetically engineered mouse-derived allograft (GEDA),"SV Rao, TS Steigedal, A Gopinathan, SN Magnussen, SS Strand, ...","Cancer Research 78 (13 Supplement), 627-627",,0,2018
"PO-425 Combined administration of anti-IL6 and anti-PD-L1 antibodies prevents ketogenic failure, reduces tumour progression, and increases overall survival in an autochthonous …","M Ferrer, CM Connell, TR Flint, D Biasci, DT Fearon, DI Jodrell, ...","ESMO Open 3 (Suppl 2), A397-A397",,0,2018
"PO-261 Multimodal mass spectrometry imaging to understand drug delivery, metabolism, response and amp; resistance in pancreatic ductal adenocarcinoma","S Ling, G Hamm, Y Wallez, FM Richards, IT Johnson, CR Dunlop, ...","ESMO Open 3 (Suppl 2), A329-A329",,0,2018
Impact of cytosolic 5'-nucleotidase 1A on chemotherapeutic resistance in pancreatic cancer,"MS Patzak, E Hessmann, V Kari, J Kitz, S Patil, FM Richards, DI Jodrell, ...","Pancreatology 18 (4), S91",,0,2018
Overall cellularity but not acellular stroma deposition increases gemcitabine accumulation in a genetically engineered mouse model of pancreatic cancer,"I Ramu, R Goetze, M Patzak, P Ströbel, B Sipos, F Richards, D Jodrell, ...","Pancreatology 18 (4), S70-S71",,0,2018
Tumor associated macrophages (TAMs) scavenge gemcitabine but not 5-FU and paclitaxel in pancreatic cancer,"SM Buchholz, R Goetze, M Patzak, F Richards, D Jodrell, H Griesmann, ...","Pancreatology 18 (4), S148-S149",,0,2018
Validation of a new model for estimating glomerular filtration rate in patients with cancer.,"E Williams, RS Geisler, I Beh, G Bertelli, R Cathomas, MJ Dooley, HM Earl, ...","Journal of Clinical Oncology 36 (15_suppl), 2565-2565",,0,2018
The CamGFR model for renal function in patients with cancer: validation and extension for use with data from isotope mass dilution spectrometry creatinine assays,"E Williams, C Whitley, JM Weaver, C Connell, S Geisler, D Giglio, ...",,,0,2018
738PStrong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first …,"P Corrie, W Qian, A Gopinathan, M Williams, R Brais, JW Valle, B Basu, ...",Annals of Oncology 28 (suppl_5),,0,2017
Using a genome-wide shRNA screen to investigate the mechanism of stroma-conferred gemcitabine resistance in pancreatic ductal adenocarcinoma,"GD Mills, N Erard, FM Richards, GJ Hannon, DI Jodrell","Cancer Research 77 (13 Supplement), 3190-3190",,0,2017
Metabolic Reprogramming of Fibroblasts to Enhance Gemcitabine Availability in Murine Pancreatic Cancer,"MS Patzak, E Hessmann, V Kari, FM Richards, DI Jodrell, SA Johnsen, ...","Pancreatology 17 (3), S13",,0,2017
"The ATR inhibitor, AZD6738, synergizes with other DNA damage response inhibitors and genotoxic drugs in pancreatic ductal adenocarcinoma cell lines: Opportunities for new …","Y Wallez, SB Koh, VSV Bhogadi, A Lau, FM Richards, DI Jodrell",MOLECULAR CANCER RESEARCH 15,,0,2017
"Abstract B19: The ATR inhibitor, AZD6738, synergizes with other DNA damage response inhibitors and genotoxic drugs in pancreatic ductal adenocarcinoma cell lines: Opportunities …","Y Wallez, SB Koh, VSV Bhogadi, A Lau, FM Richards, DI Jodrell","Molecular Cancer Research 15 (4 Supplement), B19-B19",,0,2017
Abstract OT1-04-01: Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b/randomised phase 2 study of afatinib penetration into brain metastases for patients …,"RD Baird, N Ramenatte, C Watts, A Jonson, L Jones, H Biggs, E Harrison, ...","Cancer Research 77 (4 Supplement), OT1-04-01-OT1-04-01",,0,2017
Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b/randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing …,"RD Baird, N Ramenatte, C Watts, A Jonson, L Jones, H Biggs, E Harrison, ...",CANCER RESEARCH 77,,0,2017
Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line …,"P Corrie, W Qian, A Gopinathan, M Williams, R Brais, JW Valle, B Basu, ...","Annals of Oncology 28 (Supple), 73P",,0,2017
Abstract B62: Evaluation of scheduling for triple therapy gemcitabine/CHEK1 inhibitor/WEE1 inhibitor in pancreatic cancer models,"SB Koh, FM Richards, Y Wallez, DI Jodrell","Cancer Research 76 (24 Supplement), B62-B62",,0,2016
Abstract B40: Evaluation of the combination of AZD2014 and olaparib in pancreatic cancer cells,"A Gopinathan, FM Richards, S Cosulich, B Basu, DI Jodrell","Cancer Research 76 (24 Supplement), B40-B40",,0,2016
Genetically engineered mouse-derived allografts (GEDAs): an immunocompetent mouse model of PDAC for the evaluation of novel therapeutic strategies,"S Mollard, KK Frese, A Gopinathan, FM Richards, DI Jodrell",CANCER RESEARCH 76,,0,2016
Research data supporting “Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity”,"T Flint, T Janowitz, C Connell, E Roberts, A Denton, A Coll, D Jodrell, ...",University of Cambridge,,0,2016
"CamBMT1: A proof-of-principle phase 1b/randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with …","R Baird, J Garcia-Corbacho, N Ramenatte, A Jonson, S Ahmad, DM Smith, ...","Annals of Oncology 27 (suppl_6), 408TiP",,0,2016
p53 mediates persistent Stat3 activation and contributes to stromal reprogramming in pancreatic cancer in humans and mice,"SM Wörmann, L Song, J Ai, N Diakopoulos, D Ruess, D Jodrell, ...","Zeitschrift für Gastroenterologie 54 (08), KV460",,0,2016
"The dual mTOR inhibitor, AZD2014, and castration increase intra-tumoral immune cell infiltration and anti-tumour activity in a genetically engineered mouse model of prostate cancer","C Sandi, A Ramos-Montoya, SL Filisbino, A Hughes, S Mosely, M Morrow, ...","Cancer Research 76 (14 Supplement), 389-389",,0,2016
CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number …,"J Garcia-Corbacho, F Mouliere, H Carr, JA Morris, F Marrass, DG Gale, ...","Journal of Clinical Oncology 34 (15_suppl), 11530-11530",,0,2016
MECHANISMS OF HYPERTENSION FOLLOWING VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: THE HYPAZ TRIAL,"L Yang, A McGeoch, A Hubsch, P Gajendragadkar, C McEniery, F Mir, ...","Journal of the American College of Cardiology 67 (13 Supplement), 2307",,0,2016
"Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases","RD Baird, HT Arkenau, S Deva, N Cresti, J Garcia-Corbacho, L Hogarth, ...",CANCER RESEARCH 76,,0,2016
"Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain …","RD Baird, HT Arkenau, S Deva, N Cresti, J Garcia-Corbacho, L Hogarth, ...","Cancer Research 76 (4 Supplement), P4-14-26-P4-14-26",,0,2016
Gemcitabine delivery and stromal component analysis in primary murine pancreatic tumours and liver metastasis,"L Klein, E Hessmann, TE Bapiro, K Frese, FM Richards, DI Jodrell, ...","Pancreatology 3 (16), S17",,0,2016
"Abstract A123: Preclinical evaluation of dual mTOR inhibitor, AZD2014, in prostate cancer","C Sandi, A Ramos-Montoya, SL Felisbino, S Jurmeister, B Madhu, ...","Molecular Cancer Therapeutics 14 (12 Supplement 2), A123-A123",,0,2015
"Preclinical Evaluation of Dual mTOR Inhibitor, AZD2014, in Prostate Cancer","C Sandi, A Ramos-Montoya, SL Filisbino, S Jurmeister, M Basetti, ...",American Association for Cancer Research,,0,2015
LC-MS/MS analysis of gemcitabine and its metabolites in primary murine pancreatic tumors and liver metastases,"E Hessmann, K Frese, T Bapiro, D Jodrell, T Gress, D Tuveson, ...","Zeitschrift für Gastroenterologie 53 (08), KG067",,0,2015
Mechanism-based scheduling of triple therapy gemcitabine/CHK1i/WEE1i in pancreatic cancer at submaximal yet synergistic concentrations,"SB Koh, FM Richards, E Rodriguez, SK Lyons, DI Jodrell","Cancer Research 75 (15 Supplement), 3497-3497",,0,2015
"A new mathematical model and software, to enable improved quantification and interpretation of combinatorial drug effects","GY Di Veroli, DI Jodrell, FM Richards, I Goldlust","Cancer Research 75 (15 Supplement), 2540-2540",,0,2015
Gemcitabine Cooperates with TGF beta Inhibition to Effectively Suppress Tumor Growth in Genetically Engineered Mouse Models of Pancreas Cancer,"N Schaub, T Bapiro, H Pflicke, I Chen, I Avital, D Schrump, D Jodrell, ...","ANNALS OF SURGICAL ONCOLOGY 22, S178-S179",,0,2015
32 Replication stress is a determinant of synergy between gemcitabine and Chk1 inhibition,"SB Koh, A Courtin, R Boyce, B Boyle, FM Richards, DI Jodrell","European Journal of Cancer 50, 16",,0,2014
OCULAR TOXICITIES OBSERVED WITH MEK INHIBITOR RO4987655 (CH4987655) IN A SINGLE AGENT PHASE I STUDY WITH EXTENSION IN PATIENTS WITH ADVANCED SOLID TUMORS,"S Leijen, F Barlesi, W Eberhardt, G Martinez, V Dieras, J Schellens, ...",British Journal of Clinical Pharmacology 78 (4),,0,2014
An in vitro fluorescence-based co-culture model identifies tumour microenvironment-mediated chemoresistance in pancreatic cancer,"R Xu, FM Richards, Y Lin, DI Jodrell","Cancer Research 74 (19 Supplement), 3739-3739",,0,2014
Mst2 is required for tumor progression and Yap activity,"C Escriu, K Mulder, S Woodhouse, N Benaich, S Broad, F Richards, ...","Cancer Research 74 (19 Supplement), 2016-2016",,0,2014
"gastrointestinal tumours, non-colorectal","P Corrie, W Qian, DI Jodrell, S Lao-Sirieix, P Whittaker, A Gopinathan, ...","Disclosure 2013, 001868-40",,0,2014
"Drug Development Section, Institute of Cancer Research, Sutton, Surrey, UK and* ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire UK","AL Jackman, DI Jodrell, W Gibson, TC Stephens","Purine and Pyrimidine Metabolism in Man VII: Part A: Chemotherapy, ATP …",,0,2013
"Design, synthesis and biological evaluation of a novel allosteric inhibitor of HSET that damages cancer cells with supernumerary centrosomes.","CA Watts, FM Richards, A Bender, PJ Bond, O Korb, O Kern, M Riddick, ...",Molecular Cancer Therapeutics 12 (11),,0,2013
"Abstract B96: Design, synthesis and biological evaluation of a novel allosteric inhibitor of HSET that damages cancer cells with supernumerary centrosomes.","CA Watts, FM Richards, A Bender, PJ Bond, O Korb, O Kern, M Riddick, ...","Molecular Cancer Therapeutics 12 (11 Supplement), B96-B96",,0,2013
"A phase 1 study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours","N Cresti, D Jodrell, T Arkenau, M Forster, K Donaldson, J Posner, ...","EUROPEAN JOURNAL OF CANCER 49, S160-S161",,0,2013
Abstract IA13: How much gemcitabine reaches the target… and does it matter?,"DI Jodrell, T Bapiro, N Cook, K Frese, M Jacobetz, A Neesse, F Richards, ...","Cancer Research 72 (14 Supplement), IA13-IA13",,0,2012
Abstract B33: Inhibition of stromal-derived CTGF sensitizes murine pancreatic adenocarcinoma to gemcitabine treatment.,"A Neesse, KK Frese, TE Bapiro, S Spong, DI Jodrell, DA Tuveson","Cancer Research 72 (14 Supplement), B33-B33",,0,2012
"Activity of the specific anti-ADAM17 inhibitory IgG antibody (Ab), D1 (A12) in an ovarian cancer model in vivo","FM Richards, C Tape, DI Jodrell, G Murphy","Cancer Research 72 (8 Supplement), 2724-2724",,0,2012
The aurora kinase inhibitor CYC3 synergizes with low concentrations of paclitaxel in pancreatic cancer cells in vitro,"Y Lin, BF Krippendorff, J Bramhall, T Bapiro, F Richards, D Jodrell, ...","Cancer Research 72 (8 Supplement), 1924-1924",,0,2012
Capecitabine pharmacokinetics and efficacy in spontaneous tumors occurring in a genetically engineered mouse model (GEMM) of pancreatic cancer,"A Courtin, FM Richards, TE Bapiro, DM Smith, M Williams, JL Bramhall, ...","Cancer Research 72 (8 Supplement), 3771-3771",,0,2012
Model selection and sample size adaptation: HYPAZ trial,"S Bond, A Mander, D Jodrell, J Cheryian","Trials 12 (S1), A5",,0,2011
Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma.,"G Anandappa, E Sala, HK Cheow, NJ Bird, A Shaw, AN Priest, A Gill, ...","Journal of Clinical Oncology 29 (15_suppl), TPS155-TPS155",,0,2011
The activity and pharmacokinetics of capecitabine in a mouse model (K8484) of pancreatic adenocarcinoma,"FM Richards, A Courtin, TE Bapiro, JL Bramhall, N Cook, KK Frese, ...","Cancer Research 71 (8 Supplement), 5446-5446",,0,2011
A celebration of the life and contributions of Merrill J. Egorin Obituary,D Jodrell,"CANCER CHEMOTHERAPY AND PHARMACOLOGY 67 (1), 1-3",,0,2011
"Abstract B241: Extended follow‐up from a phase I study of AS1409, a novel antibody‐cytokine fusion protein, suggests efficacy in malignant melanoma (MM)","SM Rudman, MB Jameson, P Savage, D Jodrell, F Erlandsson, D Jones, ...","Molecular Cancer Therapeutics 8 (12 Supplement), B241-B241",,0,2009
"Extended follow-up from a phase I study of AS1409, a novel antibody-cytokine fusion protein, suggests efficacy in malignant melanoma (MM)","SM Rudman, MB Jameson, P Savage, D Jodrell, F Erlandsson, D Jones, ...",MOLECULAR CANCER THERAPEUTICS 8 (12),,0,2009
Unexpected outcome (positive or negative) including adverse drug reactions: Capecitabine (oral 5-fluorouracil pro-drug) treatment for colorectal carcinoma causing ischaemic …,"TA McGoldrick, D Jodrell, S Clive",BMJ Case Reports 2009,,0,2009
Capecitabine (oral 5-fluorouracil pro-drug) treatment for colorectal carcinoma causing ischaemic chest pain,"TA McGoldrick, D Jodrell, S Clive","BMJ case reports 2009, bcr0720080449",,0,2009
"Clin. Cancer Clin. Cancer 9, 3578, 2003","K PATEL, SM GUICHARD, DI JODRELL","Journal of chromatography. B, Analytical technologies in the biomedical and …",,0,2008
"130 POSTER Structure–activity relationships for a library of C2-aryl substituted monomeric pyrrolo [2, 1-c][1, 4] benzodiazepines (PBD) antitumour agents","M Coffils, DI Jodrell, SM Guichard, JA Hartley, PW Howard, D Antonow, ...","Ejc Supplements 12 (6), 42",,0,2008
Tissue microarray technology DNA damage response proteins in sporadic colorectal cancer,"S Din, E Gibson, D Faratian, D Harrison, S Guichard, D Jodrell","GUT 57, A134-A134",,0,2008
Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to taxanes and irradiation in vitro,"K Connolly, R Mitter, M Muir, D Jodrell, S Guichard","Cancer Research 67 (9 Supplement), 3610-3610",,0,2007
Mechanisms of regulation of P-glycoprotein expression by cytokines and bacterial peptides in colon cancer cells,"D Gaya, H Johnsson, M Aldhous, M Thomson, J Satsangi, D Jodrell, ...","Cancer Research 67 (9 Supplement), 2909-2909",,0,2007
Pharmacokinetics of anticancer and non-anticancer drugs in cancer patients,"M Joerger, ADR Huitema, DJ Richel, C Dittrich, N Pavlidis, E Briasoulis, ...","PHARMACOKINETIC AND PHARMACOGENETIC PROFILING IN SOLID CANCER PATIENTS, 81",,0,2007
Downstaging inoperable colorectal liver metastases with oxaliplatin based chemotherapy,"A Law, S Clive, L Dawson, D Jodrell, G Kerr, C McLean, H Phillips, L Wall","ANNALS OF ONCOLOGY 18, VII81-VII81",,0,2007
plenary session 10: apoptosis as a drug target,"M Ranson, E Dean, T Ward, J Cummings, J Jolivet, L Robson, D Jodrell, ...",,,0,2007
Apoptosisasa drug target-XIAP inhibitors,"M Ranson, E Dean, T Ward, J Cummings, J Jolivet, L Robson, D Jodrell, ...","ANNALS OF ONCOLOGY 18, 30-30",,0,2007
143 POSTER Comparison of cell death ELISAs applied as potential surrogate biomarkers in the clinical evalution of AEG35156 (XIAP antisense),"J Cummings, TH Ward, M Ranson, NK Smith, D Jodrell, L Robson, ...","EJC Supplements 4 (12), 46-47",,0,2006
Differential metabolism of capecitabine in liver and tumor: Use of preclinical studies and fresh human hepatocytes in vitro to identify predictive markers of response,"SM Guichard, JS Macpherson, E Reid, I Mayer, DI Jodrell","Cancer Research 66 (8 Supplement), 734-735",,0,2006
Evaluation of fresh human hepatocytes and hepatoma cell lines for in vitro prediction of hepatotoxicity caused by anticancer agents,"EM Reid, DI Jodrell, SM Guichard","Cancer Research 66 (8 Supplement), 311-311",,0,2006
Cancer therapeutics: medical oncology with clinical pharmacology,D Jodrell,"BMJ 332 (7536), s43-s45",,0,2006
Establishing and characterising XIAP knockdown in HCT116 cells using shRNA.,"KC Connolly, DI Jodrell, SM Guichard","CLINICAL CANCER RESEARCH 11 (24), 9104S-9105S",,0,2005
Bcl-xl downregulation using short hairpin RNA (shRNA) sensitises HCT-116 colon cancer cells to topoisomerase I inhibition,"SM Guichard, ML Hua, DI Jodrell","Cancer Research 65 (9 Supplement), 1263-1263",,0,2005
Original Reports-PHASE I AND CLINICAL PHARMACOLOGY-Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Cancer,"R Camidge, B Reigner, J Cassidy, S Grange, M Abt, E Weidekamm, ...","Journal of Clinical Oncology 23 (21), 4719-4725",,0,2005
Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 …,"AR Norman, I Chau, T Iveson, M Hill, T Hickish, F Lofts, D Jodrell, ...","Journal of Clinical Oncology 22 (14_suppl), 3625-3625",,0,2004
Development of a real-time RT-PCR assay for the quantification of drug-metabolising enzymes and target of capecitabine,"JS Macpherson, S Guichard, DI Jodrell","BRITISH JOURNAL OF CANCER 91, S62-S62",,0,2004
Downregulation of bcl-xl expression using siRNA sensitises colon cancer cells to topoisomerase I inhibitor SN-38,"ML Hua, P Kang, S Guichard, DI Jodrell","BRITISH JOURNAL OF CANCER 91, S76-S76",,0,2004
Anti-tumor activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium (II)-based organo-metallic compounds.,"DI Jodrell, B Zeitlin, S Guichard, R Else, R Aird, M Muir, M Dodds, ...","Cancer Research 64 (7 Supplement), 714-715",,0,2004
"Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients","DP Kelsen, R Ginsberg, TF Pajak, A Maraveyes, C O'Boyle, M Cowen, ...","Cancer Investigation 22 (sup1), 1-111",,0,2004
MOLECULAR AND CELLULAR PHARMACOLOGY,"MD Hall, C Martin, DJP Ferguson, RM Phillips, TW Hambley, R Callaghan, ...","Biochemical Pharmacology 67, 2293-2307",,0,2004
"Influence of P-glycoprotein expression on the cytotoxicity of SJG-136, a new pyrrolobenzodiazepine.","SM Guichard, JS Macpherson, DE Thurston, DI Jodrell","CLINICAL CANCER RESEARCH 9 (16), 6081S-6081S",,0,2003
Determination of Novel Ruthenium Anti-Tumour Compounds in Plasma by High Performance Liquid Chromatography and Derivatization,"BD Zeitlin, C Henry, DI Jodrell, J Cummings",,,0,2003
"Experimental Therapeutics, Molecular Targets, and Chemical Biology-Glucuronidation as a Mechanism of Intrinsic Drug Resistance in Human Colon Cancer: Reversal of Resistance by …","J Cummings, BT Ethell, L Jardine, G Boyd, JS Macpherson, B Burchell, ...","Cancer Research 63 (23), 8443-8450",,0,2003
"Experimental Therapeutics, Preclinical Pharmacology-Antisense Bcl-xl Down-Regulation Switches the Response to Topoisomerase I Inhibition from Senescence to Apoptosis in …","RL Hayward, JS Macpherson, J Cummings, BP Monia, JF Smyth, ...","Clinical Cancer Research 9 (7), 2856-2865",,0,2003
"Efficacy, safety, and cost of new anticancer drugs [6](multiple letters)","H Calvert, DI Jodrell, J Cassidy, AL Harris, A Messori, S Trippoli, M Vaiani, ...","British Medical Journal 325 (7375), 1302-1303",,0,2002
Antisense Bcl-xl Knockout Switches the Response of Colon Cancer Cells to Topoisomerase I Inhibition from Senescence to Apoptosis,"RL Hayward, JS MacPherson, J Cummings, JF Smyth, DI Jodrell","Clinical Science 103 (s47), 47P-48P",,0,2002
"Particular Analytes, Including Anticancer Drugs-Determination of the Glucuronide Metabolites of the Topoisomerase I Inhibitors 7-Ethyl 10-Hydroxycamptothecin (SN-38) and NU …","J Cummings, BT Ethell, G Boyd, B Burchell, JF Smyth, DI Jodrell","Chromatographia 55, S157",,0,2002
The ninety-fifth annual general meeting of the association of physicians of Great Britain and Ireland 2001,"NDC Finlayson, S Tomlinson, AP Weetman, JMC Connell, AVS Hill, ...","QJM-Monthly Journal of the Association of Physicians 94 (11), 643-655",,0,2001
"The Subject Index for Volume 297 will appear in the December 15, 2001, issue as part of a cumulative index for the year 2001.","R Aebersold, MA Akpinar, T Bantan-Polak, A Barbot, MA Batzer, ...","Analytical Biochemistry 297, 200",,0,2001
MECHANISMS OF SIGNAL TRANSDUCTION-Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism.,"AC MacKinnon, C Waters, D Jodrell, C Haslett, T Sethi","Journal of Biological Chemistry 276 (30), 28083-28091",,0,2001
"Regular Articles-Clinical Trials-Forearm Blood Flow and Local Responses to Peptide Vasodilators: A Novel Pharmacodynamic Measure in the Phase I Trial of Antagonist G, a …","S Clive, DJ Webb, A MacLellan, A Young, B Byrne, L Robson, JF Smyth, ...","Clinical Cancer Research 7 (10), 3071-3078",,0,2001
"The in vitro metabolism of antagonist G, a broad spectrum growth factor antagonist, in the liver cytosol of mouse, rat and man","MA Mark, S Clive, AJ MacLellan, J Cummings, JF Smyth, DI Jodrell","BRITISH JOURNAL OF CANCER 83, 35-35",,0,2000
A phase I study of BBR 2778. A novel anthracenedione analogue preliminary evidence of activity in small cell lung cancer.,"L Dawson, A Bowman, DI Jodrell, R Rye, B Byrne, G Camboni, ...","BRITISH JOURNAL OF CANCER 80, 64-64",,0,1999
CLINICAL ONCOLOGY-A phase 1 study of the lipophilic thymidylate synthase inhibitor ThymitaqTM (nolatrexed dihydrochloride) given by 10-day oral administration,"DI Jodrell, A Bowman, R Rye, B Byrne, A Boddy, I Rafi, GA Taylor, ...","British Journal of Cancer 79 (5), 915-920",,0,1999
Expression of thymidylate synthase (TS) and p53 in primary colorectal adenocarcinomas and their relationship to response to protracted venous infusional (PVI) 5-fluorouracil (5 …,"N Wong, L Brett, M Stewart, PG Johnston, AM Lessells, DI Jodrell","JOURNAL OF PATHOLOGY 189, 1A-1A",,0,1999
"A clinical phase I study of the novel anthracenedione analogue, BBR 2778, administered intravenously, 3 weekly","DI Jodrell, A Bowman, R Rye, L Dawson, B Byrne, E Gamba, JF Smyth","ANNALS OF ONCOLOGY 9, 118-118",,0,1998
Novel mechanism of drug resistance to topoisomerase I (topo I) inhibitors,"J Cummings, JS Macpherson, JF Smyth, DI Jodrell","ANNALS OF ONCOLOGY 9, 62-62",,0,1998
Characterising pharmacokinetic and pharmacodynamic variability in patients receiving protracted venous infusion 5-fluorouracil as treatment for advanced colorectal cancer,"D Jodrell, R Aird, A Bowman, G Knowles, L Wall, M Stewart, J Cummings, ...",PROCEEDINGS OF THE ANNUAL MEETING-AMERICAN SOCIETY OF CLINICAL ONCOLOGY 17 …,,0,1998
Phase I and pharmacokinetic study of antagonist G. A broad spectrum neuropeptide growth factor antagonist using a rapid dose escalation strategy,"S Clive, D Jodrell, A MacLellan, A Young, M Miller, J Cummings, JF Smyth","ANNALS OF ONCOLOGY 9, 122-122",,0,1998
Cancer Treatment Reviews is extremely grateful to the following individuals who have given their time to review papers published in the journal in 1998.,"DG Altman, A Bowman, JH Chamberlain, D Cunningham, RJ Dunlop, ...","Cancer Treatment Reviews 24, 44",,0,1998
Involvement of Bcl-2 family members in drug resistance to topoisomerase I (topo I) inhibitors,"JS Macpherson, J Cummings, JF Smyth, DI Jodrell","BRITISH JOURNAL OF CANCER 78, 30-30",,0,1998
208 POPULATION PHARMACOKINETICS OF GENTAMICIN IN ONCOLOGY PATIENTS,"M Rosario, CA Sharp, DI Jodrell, AH Thomson","Therapeutic Drug Monitoring 19 (5), 599",,0,1997
Comparison of Iterative-Two Stage and Bootstrap Sampling Approaches in the Development of a Population Pharmacokinetic Model,"R Sridhara, MA Eisenberger, LM Reyno, DI Jodrell, VJ Sinibaldi, ...","IFAC Proceedings Volumes 30 (2), 141-145",,0,1997
Cisplatin and carboplatin: a guide to administration,"N LAWSON, D JODRELL, A McMURRAY","European Journal of Cancer Care 2 (1), 16-20",,0,1993
PhD Studentship–Clonal and cell state heterogeneity in breast cancer xenografts (Fixed Term),"SA Board, S Balasubramanian, G Biffi, S Bohndiek, J Brenton, K Brindle, ...",,,0,0
II-11 Chiara Fornari Development of a haematopoiesis systems pharmacology model for prediction of carboplatin induced bone marrow toxicity,"C Fornari, LO O’Connor, C Pin, JWT Yates, SYA Cheung, DI Jodrell, ...",,,0,0
PhD Studentship–Genomic and functional analysis of mutational processes in high grade serous ovarian carcinoma,"S Balasubramanian, S Bohndiek, J Brenton, K Brindle, C Caldas, J Carroll, ...",,,0,0
Supplementary information “The EGFR demonstrates linear signal transmission”,"DA Oyarzún, JL Bramhall, F López-Caamal, FM Richards, DI Jodrell, ...",,,0,0
"Our thanks to those who have helped with this issue of Expert Review of Anticancer Therapy. Listed below are the authors, referees and others who have kindly given their time …","T Abe, G Abel, R Aft, A Agaimy, A Al-Allak, P Allgood, R Andtbacka, ...",,,0,0
γ-H2AX foci formation as a pharmacodynamic marker of DNA damage,"J Wu, PH Clingen, VJ Spanswick, M Mellinas-Gomez, T Meyer, I Puzanov, ...",,,0,0
Supplemental Information to,"M Yan, M Zhang, S Ge, J Yu, M Li, J Huang, S Liu",,,0,0
A Population Approach to Predicting Post-Treatment Levels of Epirubicin in Patients with Advanced Breast Cancer,"LS Murray, DI Jodrell, JG Morrison, AW Kelman, DJ Kerr, B Whiting, ...",,,0,0
DCE-MRI in patients with mRCC: pilot study investigating possible biomarkers of antiangiogenic therapy,"AB Gill, GDS Anandappa, AN Priest, AJ Patterson, MJ Graves, I Joubert, ...",,,0,0
MST2 dependent actin-microtubule interaction is required for tumour invasion and oncogene YAP activation in oral squamous cell cancer (oSCC),"C Escriu, K Mulder, S Woodhouse, N Benaich, S Broad, F Richards, ...",,,0,0
